Table 2 Summary of univariate anlaysis for OS and PFS
median OS (months) | p* (HR [95%]) | median PFS (months) | p* | |
|---|---|---|---|---|
Age, years | ||||
< 65 | 15.9 | <0.01 | 9.3 | <0.01 |
≥ 65 | 7.4 | (3.75 [1.51-9.31]) | 3.8 | (3.10 [1.44-6.69]) |
Total dose, Gy | ||||
≤ 39 | 8.2 | <0.01 | 3.9 | <0.01 |
> 39 | 23.3 | (3.84 [1.83-8.03]) | 11.7 | (0.29 [0.14-0.59]) |
GPA | ||||
≥ 2.5 | 15.9 | 0.01 | 9.3 | 0.01 |
< 2.5 | 7.4 | (2.42 [1.18-4.93]) | 3.8 | (2.46 [1.23-4.92]) |
Extracranial metastasis | ||||
Yes | 7.6 | <0.01 | 3.8 | <0.01 |
No | 16.9 | (2.71 [1.35-5.44]) | 9.3 | (2.93 [1.48-5.79]) |
KPS | ||||
≥ 90 | 14.7 | 0.01 | 5.1 | 0.05 |
< 90 | 7.6 | (2.35 [1.19-4.63]) | 9.3 | (2.26 [0.98-5.22]) |
RPA | ||||
1 | 14.7 | 0.02 | 8.3 | 0.01 |
2-3 | 7.6 | (2.46 [1.10-5.50]) | 3.8 | (2.72 [1.25-5.89]) |
Gender | ||||
Female | 16.4 | 0.07 | 7.4 | 0.58 |
Male | 12.6 | (1.94 [0.93-4.03]) | 6.2 | (1.21 [0.61-2.41]) |
Center | ||||
CHUV | 26.4 | 0.07 | 33.3 | 0.05 |
HUG | 10.1 | (2.76 [1.12-6.80]) | 4.1 | (3.23 [1.21-8.65]) |
CHCVS | 16.4 | 9.0 | ||
Surgery | ||||
Yes | 7.5 | 0.07 | 3.8 | 0.05 |
No | 15.9 | (1.90 [0.94-3.82]) | 9.3 | (0.51 [0.25-1.01]) |
Number of brain metastasis | ||||
1 | 16.4 | 0.49 | 7.4 | 0.61 |
2-3 | 14.3 | (0.72 [0.28-1.86]) | 6.6 | (0.78 [0.30-2.02]) |
Type of primary ling cancer | ||||
SCC | 14.5 | 0.58 | 6.2 | 0.40 |
AdenoCa | 14.7 | (1.61 [0.64-4.02]) | 9.3 | (1.67 [0.70-3.99]) |
Neuroendocrine | 12.6 | (1.61 [0.64-4.02]) | 6.5 |